Jubilant Biosys allots convertible preference shares for API purchase

Fund Raising View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.0%Reaction day

₹1080.00

prior close

₹1086.50

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.1%+1.9% vs market

Pharmaceuticals peers, median of 152sector+1.0%+1.9% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Smallcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.3

15m

+0.4

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.0+1.1+1.9+1.0+1.9

Next day

+3.8+1.9+1.9+1.4+2.4

+1.4+2.0-0.6+1.3+0.1

+1.8+2.1-0.4+0.7+1.0

+0.3+1.6-1.3+0.3+0.1

+1.5+1.9-0.4+0.6+0.9

+1.8+2.2-0.5+0.9+0.9

15d

+3.4+3.2+0.3+0.6+2.8

+7.3+4.4+2.9+1.9+5.4

+2.4+0.5+1.9-2.7+5.1

-1.3-0.1-1.2-4.2+2.9

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Biosys, Jubilant Pharmova's wholly owned subsidiary, allotted 5,15,59,030 redeemable preference shares with an option to convert them into equity. Each has a face value of ₹10 and was issued at ₹100, making the allotment worth ₹515.59 crore. It formed part of the payment for Jubilant Pharmova's purchase of the API business as a going concern. The remaining ₹80 crore was paid in cash, taking total consideration to ₹595.59 crore.

Likely market impact

API purchase cost was ₹595.59 crore, including ₹80 crore cash. No new Jubilant Pharmova shares were issued, so its share count is unchanged for now.